BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38609893)

  • 21. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
    Cheng H; Hu FL
    World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China.
    Gao W; Teng G; Wang C; Xu Y; Li Y; Cheng H
    Helicobacter; 2022 Oct; 27(5):e12918. PubMed ID: 35877765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
    Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
    Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
    Wang J; Cao Y; He W; Li X
    Medicine (Baltimore); 2021 Dec; 100(51):e28323. PubMed ID: 34941132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
    Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
    Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
    Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
    Dong SQ; Singh TP; Wei X; Yao H; Wang HL
    Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
    Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
    Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
    [No Abstract]   [Full Text] [Related]  

  • 30. [Jinghuaweikang capsules combined with furazolidone-based triple or quadruple therapy as the rescue treatment for Helicobacter pylori infection: a multicenter randomized controlled clinical trial].
    Cheng H; Hu FL; Sheng JQ; An HJ; Xu L; Liu FX; Li Y; Hao Q; Zheng PY; Lu GF; Cao ZQ; Wang YP
    Zhonghua Yi Xue Za Zhi; 2016 Nov; 96(40):3206-3212. PubMed ID: 27852385
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of
    Niu M; Zhou Y; Xie Y; Li X; Tian Y; Yao L; Li X; Gao H; Bai F
    Front Pharmacol; 2022; 13():771876. PubMed ID: 35571120
    [No Abstract]   [Full Text] [Related]  

  • 32. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
    Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
    J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
    Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
    World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of furazolidone quadruple regimen plus dental plaque removal procedures as rescue treatment of refractory Helicobacter pylori infection].
    Gao W; Hu FL; Wang XM
    Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(12):836-9. PubMed ID: 21600165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
    Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
    Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of triple versus quadruple furazolidone-based eradication regimens for Helicobacter pylori infection].
    Lü Z; Xie Y; Lü N; Zhou H; Liu Z; Zhu X; Chen Y; He X; Liu D; Ma J
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):572-5. PubMed ID: 24762683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
    Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
    Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.